Antenatal allopurinol for reduction of birth asphyxia induced brain damage (ALLO-Trial); a randomized double blind placebo controlled multicenter study

BACKGROUND Hypoxic-ischaemic encephalopathy is associated with development of cerebral palsy and cognitive disability later in life and is therefore one of the fundamental problems in perinatal medicine. The xanthine-oxidase inhibitor allopurinol reduces the formation of free radicals, thereby limiting the amount of hypoxia-reperfusion damage. In case of suspected intra-uterine hypoxia, both animal and human studies suggest that maternal administration of allopurinol immediately prior to delivery reduces hypoxic-ischaemic encephalopathy. METHODS/DESIGN The proposed trial is a randomized double... Mehr ...

Verfasser: Kaandorp, J.
Benders, M.
Rademaker, C.
Torrance, H.
Oudijk, M.
de Haan, T.
Bloemenkamp, K.
Rijken, M.
van Pampus, M.
Bos, A.
Porath, M.
Bambang Oetomo, S.
Willekes, C.
Danilo Gavilanes, A.
Wouters, M.
van Elburg, R.
Huisjes, A.
Bakker, S.
van Meir, C.
von Lindern, J.
Dokumenttyp: Journal article
Erscheinungsdatum: 2010
Verlag/Hrsg.: BioMed Central Ltd.
Schlagwörter: Humans / Hypoxia-Ischemia / Brain / Asphyxia Neonatorum / Allopurinol / Phosphopyruvate Hydratase / Xanthine Oxidase / Nerve Growth Factors / S100 Proteins / Free Radical Scavengers / Prenatal Care / Multivariate Analysis / Regression Analysis / Prospective Studies / Pilot Projects / Double-Blind Method / Pregnancy / Infant / Newborn / Netherlands / Female / Fetal Hypoxia / S100 Calcium Binding Protein beta Subunit / Biomarkers
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26827855
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/2440/88489